Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TNF Pharmaceuticals, Inc. - Common Stock (NQ:TNFA)

0.1645 -0.0033 (-1.97%)
Streaming Delayed Price Updated: 3:20 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TNF Pharmaceuticals, Inc. - Common Stock

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
From TNF Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.